COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies

BACKGROUND: Patients with autoimmune systemic diseases (ASDs) represent a frail population during the ongoing COVID-19 pandemic. The vaccination is the major preventive measure; however, a significant number of ASD patients show an impaired production of anti-COVID-19 neutralizing antibodies (NAb),...

Descripción completa

Detalles Bibliográficos
Autores principales: Gragnani, Laura, Visentini, Marcella, Lorini, Serena, La Gualana, Francesca, Santini, Stefano Angelo, Cacciapaglia, Fabio, Tavoni, Antonio, Cuomo, Giovanna, Fallahi, Poupak, Iannone, Florenzo, Antonelli, Alessandro, Casato, Milvia, Zignego, Anna Linda, Ferri, Clodoveo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
VSI:Autoantibodies in disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472465/
https://www.ncbi.nlm.nih.gov/pubmed/36120415
http://dx.doi.org/10.1016/j.jtauto.2022.100164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472465/
https://www.ncbi.nlm.nih.gov/pubmed/36120415
http://dx.doi.org/10.1016/j.jtauto.2022.100164

Ejemplares similares